VYCO — what changed in the latest 10-Q
A section-by-section comparison of VYCO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +14 | −6 | ~13 | 11 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 6 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Other information | Text added/removed | 0 | 0 | ~1 | 9 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Comparison of the Six Months Ended June 30, 2026 to the Six Months Ended June 30, 2025
Vycor Medical recorded revenue of $841,665 from the sale of its products for the six months ended June 30, 2026, a decrease of $58,643, or 7%, over the same period in 2025, the majority of the decrease being from international markets, which can often be lumpy with large orders sometimes falling in …
NovaVision recorded revenues of $35,139 for the six months ended June 30, 2026, an increase of $2,716 over the same period in 2025. Gross margin was 95%, compared to 93% for the same period in 2025.
Research & Development expenses were $0 for the six months ended June 30, 2026 compared to $9,963 for the same period in 2025, reflected new product development in the Vycor Medical division in 2025.
Selling, general and administrative expenses decreased by $57,665 to $638,076 for the six months ended June 30, 2026 from $695,741 for the same period in 2025. Included within Selling, General and Administrative Expenses are non-cash charges for stock-based compensation as the result of amortizing n…
Text removed vs the prior filing · source: 10-Q · 2026-05-15
The following table shows liquidity data as of March 31, 2026 and December 31, 2025:
Accounts receivable, inventory and other current assets $477,413 $476,440 $973
The following table shows cash flow for the periods ended March 31, 2026 and 2025:
Operating Activities. Cash provided by (used in) operating activities comprises net loss adjusted for non-cash items and the effect of changes in working capital and other activities.
The following table shows the principal components of cash provided by (used in) operating activities during the three months ended March 31, 2026 and 2025, with a commentary of changes during the periods and known or anticipated future changes:
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice